Drug Trial Radar · NCT07029971
A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
16
Actual
Start
Jun 23, 2025
Primary completion
Dec 23, 2025
Study completion Dec 23, 2025
Sponsor
- Lead sponsor
- Vial Australia Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if BB-TL1A-VIAL-HLE is safe in healthy adults and is safe and effective in treating adults with moderate-to-severe ulcerative colitis. The main questions it aims to answer are: Is the intervention safe in healthy adults and in adults with moderate-to-severe ulcerative colitis? Is the intervention effective in treating adults with moderate-to-severe ulcerative colitis? Researchers will compare the Phase 1b arm to a historical treatment arm to estimate the drug's effect size and see if the study drug is at least as effective as a relevant benchmark. Participants will: * Attend the clinical research site several times over the course of \~1 year * Have blood and urine samples taken * Undergo physical examinations * Receive one injection of the study drug
Conditions
- Ulcerative Colitis (UC)
Interventions
BB-TL1A-VIAL-HLEBiological
Anti-TL1A monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting or intolerable treatment related adverse eventsTime frame: From enrollment to the end of the follow up period at Day 355
- Incidence, severity and causal relationship of treatment emergent AEs (TEAEs) and withdrawals due to TEAEsTime frame: From enrollment to the end of the follow up period at Day 355
- Incidence and magnitude of abnormal laboratory findingsTime frame: From enrollment to the end of the follow up period at Day 355
- Abnormal and clinically relevant changes in vital signs, blood pressure and electrocardiogram parametersTime frame: From enrollment to the end of the follow up period at Day 355
- Percentage of participants who achieve endoscopic improvement at 12 weeks post-dose (Ph-1b)Time frame: From enrollment to end of induction period at 12 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Dymocks Building, WellShare Site
Sydney, New South Wales, Australia
Arcadia Pittwater Private Hospital (Operated by Battery Bio)
Warriewood, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.